EU Horizon funding · Belgium · NACE 21
Horizon Europe funding for pharmaceutical companies in Belgium
NACE 21 · Manufacture of basic pharmaceutical products and pharmaceutical preparations
15 pharmaceutical companies in Belgium received €35M in EU research and innovation funding across 47 Horizon Europe and Horizon 2020 projects starting between 2014 and 2026; 16% of the money went to SMEs.
- EU contribution
- €35M
- 2014–2026 project starts
- Funded companies
- 15
- 6 of them SMEs
- Projects
- 47
- Horizon Europe and Horizon 2020
- Share to SMEs
- 16%
- €5.8M to SMEs
Industry is known only for companies in Belgium that we matched to the national business register; funded companies we could not match are counted on the Belgium country page but not here.
In numbers
Pharmaceutical companies in Belgium rank 12th of 40 industry divisions in Belgium by total EU funding received.
Of the total, Horizon 2020 (2014–2020) accounts for €22M across 28 projects and Horizon Europe (2021–2027) for €13M across 19 projects.
The strongest start year was 2014, when projects worth €14M to these companies began.
The largest funding route was the Research and Innovation Action (RIA) with €21M (60% of the total, 20 projects). The EIC Accelerator added €4.3M for 2 projects.
GlaxoSmithKline Biologicals (Rixensart) is the largest recipient with €14M over 1 project; the 10 largest recipients together received 98% of the total.
The average funded company received €2.4M; 40% of the companies are SMEs.
By programme
Horizon 2020 2014–2020
€22M
28 projects · 62% of the total
Horizon Europe 2021–2027
€13M
19 projects · 38% of the total
Funding by start year
EU contribution to these companies, by the year their project started.
| Year | EU contribution |
|---|---|
| 2014 |
€14M
|
| 2015 |
€561k
|
| 2016 |
€633k
|
| 2017 |
€2M
|
| 2018 |
€808k
|
| 2019 |
€949k
|
| 2020 |
€715k
|
| 2021 |
€4.8M
|
| 2022 |
€2.9M
|
| 2023 |
€4.7M
|
| 2024 |
€582k
|
| 2025 |
€525k
|
| 2026 |
€2.1M
|
2014–2020 starts (mostly Horizon 2020) 2021 onwards (Horizon Europe)
Largest recipients
Companies with the highest EU contribution, Horizon Europe and Horizon 2020 combined.
| # | Company | Programmes | Projects | EU contribution |
|---|---|---|---|---|
| 1 | GlaxoSmithKline Biologicals Rixensart | Horizon 2020 | 1 | €14M |
| 2 | Janssen Pharmaceutica Beerse | Horizon 2020, Horizon Europe | 27 | €9.5M |
| 3 | Perseus Biomics SME Leuven | Horizon Europe | 2 | €3.2M |
| 4 | Quantoom Biosciences Nivelles | Horizon Europe | 3 | €2.8M |
| 5 | Inteliphage SME Ottignies-Louvain-la-Neuve | Horizon Europe | 1 | €1.8M |
| 6 | Obulytix Gent | Horizon Europe | 1 | €1.5M |
| 7 | Zoetis Belgium Ottignies-Louvain-la-Neuve | Horizon 2020 | 5 | €504k |
| 8 | Namsa Belgium Diest | Horizon 2020 | 1 | €460k |
| 9 | Advanced Practical Diagnostics SME Turnhout | Horizon 2020 | 1 | €447k |
| 10 | Exothera Charleroi | Horizon Europe | 1 | €410k |
Funding schemes
How the money reached these companies.
-
Research and Innovation Action (RIA) €21M20 projects HORIZON-RIA · RIA 60%
-
Marie Skłodowska-Curie Actions €4.9M15 projects HORIZON-TMA-MSCA-DN · MSCA-ITN · MSCA-ITN-ETN 14%
-
EIC Accelerator €4.3M2 projects HORIZON-EIC-ACC-BF 12%
-
Innovation Action (IA) €2.1M5 projects HORIZON-IA · IA 6%
-
Joint Undertaking actions (Horizon Europe) €1.5M2 projects HORIZON-JU-IA · HORIZON-JU-RIA 4%
-
European Research Council (ERC) €729k1 project ERC-COG 2%
Notable recent projects
Recent projects with the largest EU contribution to these companies. Links open the project on CORDIS.
-
END2AMR
European Novel Drug research to Address Microbial infections and drug Resistance
Started 2026 Horizon Europe Joint Undertaking actions (Horizon Europe) Total EU contribution €15M to these companies €1.5M
-
PROCRYSTAL
Crystallisation towards efficient and sustainable biomanufacturing
Started 2025 Horizon Europe Marie Skłodowska-Curie Actions Total EU contribution €3.3M to these companies €525k
-
SOLVE
Sustainable COVID-19 Vaccination for Long-term Vaccine Immunity and Effectiveness
Started 2024 Horizon Europe Research and Innovation Action (RIA) Total EU contribution €9M to these companies €456k
-
IDEAS
Improving Drug Efficacy with next-generation AmorphouS materials and trained experts
Started 2026 Horizon Europe Marie Skłodowska-Curie Actions Total EU contribution €4.3M to these companies €289k
-
MetaExplore
Ultrahigh-throughput exploration of metagenomic sequence space to discover and engineer novel biocatalysts and bioactive compounds
Started 2026 Horizon Europe Marie Skłodowska-Curie Actions Total EU contribution €4.6M to these companies €289k
Other funded industries in Belgium
| Industry (NACE) | Companies | Projects | To SMEs | EU contribution |
|---|---|---|---|---|
| 71 Architecture & Engineering | 112 | 429 | 51% |
€200M
|
| 62 Software & IT Services | 153 | 384 | 71% |
€164M
|
| 72 Research & Development | 93 | 311 | 78% |
€159M
|
| 70 Management Consulting | 128 | 448 | 80% |
€130M
|
| 82 Business Support Services | 31 | 189 | 79% |
€62M
|
| 74 Other Professional & Technical Services | 30 | 87 | 93% |
€47M
|
| 20 Chemicals Manufacturing | 37 | 107 | 17% |
€47M
|
| 46 Wholesale | 58 | 140 | 26% |
€46M
|
| 26 Electronics Manufacturing | 41 | 101 | 48% |
€46M
|
| 27 Electrical Equipment Manufacturing | 19 | 70 | 79% |
€44M
|
Pharmaceutical in other countries
Get company lists in Claude
Ask Claude for companies by industry, size and region, straight from official European business registers, and export the list as CSV.
Source and method
Source: CORDIS – © European Union, 1994–2026, CC BY 4.0. Data modified: aggregated by EU Company Leads. Project and participant data from CORDIS (Horizon Europe and Horizon 2020 project datasets), licensed under CC BY 4.0.
We count organisations that CORDIS lists as private for-profit companies (activity type PRC) with an EU contribution above zero. Amounts are the EU contribution to those companies, not total project budgets; years are project start years. Industries use NACE Rev. 2.1 from the national business registers of France, Finland, Belgium, Estonia, Sweden and Czech Republic and are only known for companies matched to those registers. Figures computed Nov 17, 2026.